
BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Taiwan's OBI Pharma discontinues cancer molecule development

July 7, 2022 | News

OBI Pharma announces discontinuation of the Phase 1/2 study of its antibody- OBI 888 to focus on other priority cancer programs



OBI Pharma, a Taiwan biopharma company announced discontinuation of the Phase 1/2 Study for OBI 888, a Globo H antibody, upon completion of enrollment in our investigative sites.

“We are pleased that the preliminary data from our Phase 1/2 study demonstrated that OBI 888 is a safe and well tolerated product and showed some trends of efficacy. However, due to the higher antibody amount required for the OBI-888 treatment compared to the ADC, OBI-999, and an unexpected low drug yield at the large manufacturing scale, OBI-888 no longer fulfills our goal of developing cost-effective therapies for cancer patients. We have therefore decided to discontinue OBI-888 development and focus on our novel cancer pipeline under Phase 3 (Adagloxad Simolenin-vaccine) and Phase 2 (OBI 999-ADC, OBI 833-vaccine and OBI 3424-small molecule) clinical development. The OBI-888 clinical study report is estimated to be finalized in Q4, 2022 and presented at a future medical conference. OBI Pharma is excited to develop and validate our novel anti-Globo H, AKR1C3 and Trop 2 pipeline to fulfill unmet medical needs of cancer patients,” stated, Michael Chang, OBI Pharma Chairman and CEO.